Salute e Benessere

Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®)…

Media ReleaseCOPENHAGEN, Denmark; May 14, 2025 Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings Genmab A/S (Nasdaq:GMAB)announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination across disease settings in patients with...
Nasdaq GlobeNewswire
14/05/2025

Exoskeleton Market worth $2.03 billion by 2030 - Exclusive Report by…

Browse in-depth TOC on "Exoskeleton Market" 192 – Tables58 – Figures276 – Pages Browse in-depth TOC on "Exoskeleton Market" 192 – Tables 58 – Figures 276 – Pages Exoskeleton Market Report Scope: By mobility, mobile segment to lead market share during forecast period. The mobile segment is expected to lead the market share during the forecast period due to the wide applicability of mobile exoskeletons across healthcare, industrial, and defense sectors. Unlike stationary...
PR Newswire
14/05/2025

Point of Care Diagnostics Market worth $68.5 billion by 2030 - Exclusive Report…

Browse in-depth TOC on "Point of Care Diagnostics Market"55 - Tables85 - Figures226 - Pages Browse in-depth TOC on "Point of Care Diagnostics Market" 55 - Tables 85 - Figures 226 - Pages By Based on Product,the market consists of Glucose Monitoring, Infectious Disease Testing, Cardiometabolic Monitoring, Pregnancy & Fertility Testing, and other categories. The global market continues to see Glucose Monitoring as the dominant point of care product in 2024 because…
PR Newswire
14/05/2025

CAST SURGICAL CLINICAL TRIAL MANUSCRIPT ACCEPTED FOR PUBLICATION BY THE JOURNAL…

"The results of this study clearly indicate that even for experienced surgeons the LevaLap™ 1.0 device provides important benefits in terms of improved ease, control, speed, and safety for accessing the abdomen with the Veress needle during minimally invasive surgery", stated corresponding author Ricardo Azziz, MD, MPH. "The value of this device will be even greater considering the large number of surgeons around the globe performing these types of surgery, regardless of surgeon's…
PR Newswire
14/05/2025

TELUS Health acquires Workplace Options, top provider of wellbeing services to…

VANCOUVER, BC and TORONTO, May 14, 2025 /PRNewswire/ -- TELUS Corporation ("TELUS") (TSX: T) (NYSE: TU) today announced a strategic partnership with GTCR, a leading private equity investor with extensive expertise across the healthcare landscape, supporting TELUS Health's recently announced acquisition of Workplace Options. Last week, TELUS Health announced the acquisition of Workplace Options for cash of approximately $500 million (US$350 million), net of assumed debt of approximately…
PR Newswire
14/05/2025

Notice to attend the annual general meeting in Scibase Holding AB (publ)

Right to participate and notice of participation Right to participate and notice of participation A shareholder who wishes to participate at the general meeting must: Nominee-registered shares Shareholders whose shares are held in the name of a nominee must, in order to be able to participate at the general meeting and exercise their voting right, temporarily re-register the shares in their own name in the share register maintained by Euroclear Sweden AB (so-called voting right registration)...
PR Newswire
14/05/2025

Caron Expands Cleanroom Solution Portfolio

Included in the Cleanroom Upgrade: Included in the Cleanroom Upgrade: "Adding the Cleanroom solution to our portfolio further expands our ability to support our customers working in critical applications across the pharmaceutical and personalized medicine markets," statedJay Abramo, Chief Commercial Officer,Caron Scientific. About Caron ScientificWith over 40 years in the industry, Caron Scientific specializes in designing and manufacturing high-quality controlled environment...
PR Newswire
14/05/2025

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and…

- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial -- Closed a public offering on May 8, 2025, raising the Company's cash balance and extending its cash runway into the first quarter of 2026 -ROCKVILLE, Md., May14, 2025(GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet...
Nasdaq GlobeNewswire
14/05/2025

FAMAR Group announces acquisition of sterile manufacturing site in Homburg…

"The Homburg site offers world-class sterile infrastructure, newly installed QC and microbiology laboratories, and a skilled workforce," said Konstantinos Rengis, CEO of FAMAR Group. "This investment aligns with our strategy to grow in differentiated dosage forms and expand our capacity to support global customers with manufacturing services of the highest standards. We are proud to welcome the Homburg team to the FAMAR family and look forward to building a strong future…
PR Newswire
14/05/2025

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for…

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this yearORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) on track with data expected across all three indications this year with first-in-class potential in NT2 and IHORX142 on track to initiate first-in-human studies for the treatment of neurological and neurodegenerative disorders...
Nasdaq GlobeNewswire
14/05/2025

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small…

Collaboration combines Novo Nordisk's scientific leadership in obesity and cardiometabolic diseases with Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop multiple oral small molecule therapies for key GPCR targets, including GLP-1, GIP and glucagon receptorsSepterna is eligible to receive approximately 2.2 billion US dollars, including more than 200 million dollars in upfront and near-term paymentsSouth San Francisco, California, US...
Nasdaq GlobeNewswire
14/05/2025

Polpharma Group Calls for Urgent Action to Protect early equitable access to…

Polpharma Group Joins the Call to Action to Finalize Pharmaceutical Reform and Secure Early and Sustainable Healthcare for European Patients Commitment to Health Security Public health is a fundamental right. As EU Health Ministries approach the final stages of negotiations on the future of Europe's pharmaceutical rules, Polpharma Group emphasizes the need to ensure that every European has access to the medicines they need. This is about avoiding shortages, bringing production back to...
Nasdaq GlobeNewswire
14/05/2025

Shamekh SIV Solutions Announces $5.8 Billion Global Pharmaceutical Manufacturing…

At the heart of this ambitious venture lies a critical focus on securing and diversifying supply chains to safeguard national interests. By establishing state-of-the-art manufacturing facilities in Saudi Arabia and across the Americas, Shamekh SIV Solutions is reducing dependency on fragile global supply networks and ensuring a resilient, reliable flow of essential medical products. This strategic approach not only bolsters national security but also reinforces U.S. leadership in healthcare…
PR Newswire
14/05/2025

Noster research: Gut bacteria-derived molecule found to shrink fat cells and…

The compound—HYA (10-hydroxy-cis-12-octadecenoic acid)—is made when certain gut bacteria, including Lactobacillus, metabolize linoleic acid, a common dietary fat. While HYA has previously been shown to support gut health and inflammation control, this study is the first to demonstrate that it directly alters the behavior of fat cells themselves. The compound—HYA (10-hydroxy- cis -12-octadecenoic acid)—is made when certain gut bacteria, includingLactobacillus, metabolize linoleic acid, a...
PR Newswire
14/05/2025

NCCN Joins Global Cancer Organizations for First-Ever International…

"We strive every day to improve access to high-quality, high-value, patient-centered cancer care for all people globally," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "We are proud to not only attend but also sponsor this important meeting as part of our commitment to international collaboration against cancer. It is crucial that every country or region has access to cancer plans based on the best available evidence to optimize care for people touched by cancer…
PR Newswire
14/05/2025

New global Digital Economy Trust Index exposes correlation between GDP growth…

The Digital Economy Trust Index is intended to provide a comprehensive view of how individuals interact with, trust, and adopt digital systems. This helps businesses, policymakers and technology providers understand key trust drivers and barriers and ultimately grow trust in the digital economy to stimulate broader economic growth. Of the 18 distinct dimensions investigated in all markets, those that correlate most closely with the overall trust score were trust that new technology makes payment…
PR Newswire
14/05/2025

SK chemicals Strengthens Position in Cosmetics Packaging with Circular Materials…

Now in its 29th year, China Beauty Expo is the largest beauty trade show in Asia, drawing more than 400,000 visitors from over 80 countries. The event brings together global cosmetics brands and supply chain players—from R&D and manufacturing to packaging and logistics—to showcase cutting-edge trends, technologies, and products. This year's expo featured over 3,200 exhibitors and more than 10,000 brands. Now in its 29th year, China Beauty Expo is the largest beauty trade show inAsia…
PR Newswire
14/05/2025

Kaerus Bioscience's lead candidate KER-0193 granted Orphan Drug Designation and…

FXS is an inherited condition, affecting about 1 in 7,000 males and 1 in 11,000 females, for which there are currently no approved treatments. It is the most common cause of inherited autism and intellectual disability, accounting for approximately 1 per cent of such cases globally. FXS is an inherited condition, affecting about 1 in 7,000 males and 1 in 11,000 females, for which there are currently no approved treatments. It is the most common cause of inherited autism and intellectual...
PR Newswire
14/05/2025

Hansa Biopharma data at the 2025 PNS Annual Meeting demonstrates potential of…

Hitto Kaufmann, Chief R&D Officer, Hansa Biopharma said, "We are pleased to be able to share more detail around the positive data from our 15-HMedIdeS-09 Phase 2 study, which demonstrated the significant potential imlifidase could have in combination with standard of care IVIg for patients with GBS. We know that IgG is a key driver of inflammatory attacks on peripheral nerves and has been clinically linked to the severity and progression of GBS, and that there is a clear and urgent need…
PR Newswire
14/05/2025

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, May14, 2025(GLOBE NEWSWIRE) --Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDate Number of Shares Outstanding Total number of voting rightsTotal voting rights,...
Nasdaq GlobeNewswire
14/05/2025

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial

Press ReleaseNicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide were statistically significant or trended in favor of NCX 470; likewise those that respond to prostaglandin analogsEpiscleral venous pressure changes did not show a trend vs. placeboSafety profile is consistent with that of the first Phase 3 trial, Mont BlancNCX 470 intraocular pressure lowering efficacy and safety...
Nasdaq GlobeNewswire
14/05/2025

Nyxoah Reports First Quarter Financial and Operating Results

REGULATED INFORMATIONNyxoah Reports First Quarter Financial and Operating ResultsCompany On Track for Anticipated PMA Approval in the Second Quarter of 2025Successfully Completed FDA Validation Requirements, Final Site Inspection in ProgressMont-Saint-Guibert, Belgium – May 14, 2025, 7am CET / 1am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep...
Nasdaq GlobeNewswire
14/05/2025

Preclinical insights into dosing for first-in-human in vivo liver-directed gene…

PRESS RELEASE Preclinical insights into dosing for first-in-humanin vivoliver-directed gene therapy for MMA delivered in an oral presentation at the ASGCT Annual MeetingMilan, ITALY – 14 May 2025– Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, presented positive preclinical insights into dosing for the first-in-humanin vivoliver-directed gene therapy for methylmalonic acidemia (MMA) in an oral...
Nasdaq GlobeNewswire
14/05/2025

Cariflex Opens World's Largest Polyisoprene Latex Plant in Singapore, Following…

The inauguration ceremony was officiated by Dr Tan See Leng, Singapore's Minister for Manpower and Second Minister for Trade and Industry, and attended by H.E. Hong Jin Wook, Ambassador of the Republic of Korea, Mr Kim Jong Hyun, Chief Executive Officer of DL Chemical, Mr Ryu Sang Woo, Chief Executive Officer of Cariflex, Mr Prakash Kolluri, Member of Cariflex Board of Director and President, Polymer Business, Kraton, and Mr Lim Wey-Len, Executive Vice President of the Singapore Economic…
PR Newswire
14/05/2025
Altri  Comunicati